609
Views
3
CrossRef citations to date
0
Altmetric
Original Articles

Impact of a vincristine dose cap on the incidence of neuropathies with DA-EPOCH-R for the treatment of aggressive lymphomas

ORCID Icon, , , , , , , , & show all
Pages 1126-1132 | Received 02 Sep 2019, Accepted 03 Dec 2019, Published online: 26 Dec 2019

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Nancy L. Bartlett. (2020) The justification of vincristine dose capping: tradition, tradition…tradition!. Leukemia & Lymphoma 61:5, pages 1007-1009.
Read now

Articles from other publishers (2)

Zdravko Mitrovic, Dino Dujmovic, Ozren Jaksic, Sandra Basic Kinda, Petar Gacina, Vlatka Perisa, Zeljko Prka, Barbara Dreta, Davor Galusic, Hrvoje Holik, Vlatko Pejsa & Igor Aurer. (2023) Dose‐adjusted EPOCH and rituximab ( DA‐EPOCH‐R ) in older patients with high‐risk aggressive diffuse large B‐cell lymphoma: A real‐life multicenter study by the Croatian Cooperative Group for Hematologic diseases ( KroHem ) . European Journal of Haematology 110:6, pages 725-731.
Crossref
Daniel L. Hertz, Cindy Tofthagen & Sara Faithfull. 2021. Diagnosis, Management and Emerging Strategies for Chemotherapy-Induced Neuropathy. Diagnosis, Management and Emerging Strategies for Chemotherapy-Induced Neuropathy 19 51 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.